The views, information, or opinions expressed in the Industry News RSS feed belong solely to the author and do not necessarily represent those of IDEX Health & Science and its employees.
Article obtained from Photonics RSS Feed.
A tumor-highlighting technology called OTL38 enhances the visualization of lung cancer tissue through near-infrared imaging, providing surgeons with a significantly better chance of finding and removing more cancer than previously possible. The results of a phase 2 clinical trial for OTL38 were presented at the 56th Annual Meeting of The Society of Thoracic Surgeons, Jan. 25-28, 2020, in New Orleans. Six institutions participated in the trial — the University of Pittsburgh, the University of Pennsylvania, Harvard University, Cleveland Clinic, Leiden University, and the University of Texas MD Anderson Cancer Center.
OTL38 is composed of near-infrared dye and a targeting molecule. The molecule attaches to folic-acid-based…READ MORE